MX2007000724A - Uso de anfiregulina como un agente protector en el dano hepatico agudo. - Google Patents

Uso de anfiregulina como un agente protector en el dano hepatico agudo.

Info

Publication number
MX2007000724A
MX2007000724A MX2007000724A MX2007000724A MX2007000724A MX 2007000724 A MX2007000724 A MX 2007000724A MX 2007000724 A MX2007000724 A MX 2007000724A MX 2007000724 A MX2007000724 A MX 2007000724A MX 2007000724 A MX2007000724 A MX 2007000724A
Authority
MX
Mexico
Prior art keywords
hepatic injury
amphiregulin
acute
hepatic
acute hepatic
Prior art date
Application number
MX2007000724A
Other languages
English (en)
Inventor
Valtuena Jesus Prieto
Zaragoza Matias Antonio Avila
Garcia-Trevijano Elena Ruiz
Lasarte Carmen Berasain
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of MX2007000724A publication Critical patent/MX2007000724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe el uso de anfiregulina en la fabricacion de un medicamento util para el tratamiento del dano hepatico agudo, que se suministra por ejemplo para potenciar una reaccion protectora endogena primaria del tejido hepatico frente al dano hepatico agudo, para promover la sintesis de DNA en hepatocitos, para prevenir la muerte de hepatocitos en tejido hepatico en pacientes con dano hepatico agudo, para estimular la regeneracion del parenquima hepatico remanente tras un dano hepatico agudo de cualquier etiologia, par estimular la regeneracion hepatica tras una tepatectomia parcial, como farmaco hepatoprotector en pacientes con dano hepatico agudo de cualquier etiologia y/o como farmaco hepatoprotector y estimulante de la regeneracion hepatocitaria en pacientes receptores de transplante hepatico de vivo o de cadaver.
MX2007000724A 2004-07-20 2005-06-21 Uso de anfiregulina como un agente protector en el dano hepatico agudo. MX2007000724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401776A ES2246156B1 (es) 2004-07-20 2004-07-20 Uso de la anfiregulina como un agente protector en el daño hepatico agudo.
PCT/ES2005/000348 WO2006021599A1 (es) 2004-07-20 2005-06-21 Uso de la anfiregulina como un agente protector en el daño hepático agudo

Publications (1)

Publication Number Publication Date
MX2007000724A true MX2007000724A (es) 2007-05-23

Family

ID=35875097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000724A MX2007000724A (es) 2004-07-20 2005-06-21 Uso de anfiregulina como un agente protector en el dano hepatico agudo.

Country Status (11)

Country Link
US (1) US20080064629A1 (es)
EP (1) EP1780218A1 (es)
JP (1) JP2008506754A (es)
CN (1) CN101031585A (es)
AU (1) AU2005276466A1 (es)
BR (1) BRPI0513595A (es)
CA (1) CA2574507A1 (es)
ES (1) ES2246156B1 (es)
MX (1) MX2007000724A (es)
RU (1) RU2007105994A (es)
WO (1) WO2006021599A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180021736A (ko) * 2015-06-15 2018-03-05 바이탈 쎄러피스, 인코포레이티드 세포의 항아폽토시스, 생존, 또는 증식을 유도하기 위한 조성물 및 방법
CN108220320A (zh) * 2018-02-12 2018-06-29 武汉伊艾博科技有限公司 人双调蛋白克隆至人工改造的表达载体pGEX-4T-1及其原核可溶性表达的研究

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
CA2237543A1 (en) * 1995-12-22 1997-07-03 Innogenetics N.V. New form of amphiregulin, methods for producing and using the same and compositions comprising the same
US20010051358A1 (en) * 1996-04-10 2001-12-13 Henrik S. Olsen Extracellular/epidermal growth factor-like protein
AU752206B2 (en) * 1997-04-11 2002-09-12 Human Genome Sciences, Inc. Extracellular/epidermal growth factor like protein

Also Published As

Publication number Publication date
WO2006021599A1 (es) 2006-03-02
AU2005276466A1 (en) 2006-03-02
EP1780218A1 (en) 2007-05-02
CN101031585A (zh) 2007-09-05
BRPI0513595A (pt) 2008-05-13
CA2574507A1 (en) 2006-03-02
RU2007105994A (ru) 2008-08-27
US20080064629A1 (en) 2008-03-13
JP2008506754A (ja) 2008-03-06
ES2246156B1 (es) 2007-03-16
ES2246156A1 (es) 2006-02-01
WO2006021599A8 (es) 2006-06-29

Similar Documents

Publication Publication Date Title
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
ECSP10010735A (es) Compuestos químicos 251
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
CR11723A (es) Agente para tratar enfermedad
ATE395905T1 (de) Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
ITMI20041820A1 (it) Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico.
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
IN2015DN02729A (es)
TW200714293A (en) Pharmaceutical composition containing hardly water souble pharmaceutical substance
BRPI0720500A8 (pt) Preparação líquida transdérmica
NO20076405L (no) Anvendelse av 24-nor-UDCA
SE0300098D0 (sv) Use of cyclin D1 inhibitors
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
MX2007000724A (es) Uso de anfiregulina como un agente protector en el dano hepatico agudo.
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
DE602007009199D1 (de) Verfahren zur bestimmung pseudoallergischer reaktionen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal